6R-BH4 Pulmonary Arterial Hypertension Study

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

October 31, 2008

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

sapropterin dihydrochloride (6R-BH4)

2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days

Trial Locations (1)

37232

Vanderbilt Medical Center, Nashville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

BioMarin Pharmaceutical

INDUSTRY

lead

Vanderbilt University

OTHER